Skip to content

A preliminary investigation on the efficacy and mechanism of postoperative application of Sophora granules in triple-negative breast cancer patients

A preliminary investigation on the efficacy and mechanism of postoperative application of Sophora granules in triple-negative breast cancer patients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004579
Enrollment
Unknown
Registered
2021-03-16
Start date
2021-04-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Triple negative breast cancer

Interventions

Sponsors

Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who have undergone modified radical mastectomy or breast-conserving surgery for triple-negative breast cancer; 2. Aged 18 and 80 years; 3. have completed postoperative adjuvant chemotherapy and are on a first-line regimen (AT/TAC), and have not received chemotherapy or breast cancer-related medications within 1 month; 4. do not have significant cardiopulmonary or renal insufficiency; 5. Barthel Index score > 70.

Exclusion criteria

Exclusion criteria: 1. Combination of other malignant tumors, other autoimmune related diseases and endocrine diseases; 2. Patients with unclear pathological diagnosis or those who do not meet the staging of the group to which they belong; 3. Patients with significant cardiac, hepatic, renal, cerebral, neurological or hematopoietic dysfunction; 4. Women who are pregnant, lactating or preparing for pregnancy; 5. Patients with allergies or known hypersensitivity to therapeutic agents or components; 6. Patients with known distant metastases or recurrence; 7. Patients who are participating in other clinical drug trials; 8. Patients with a Barthel Index score <=60 on the daily living ability scale.

Design outcomes

Primary

MeasureTime frame
Serum tumor markers;mtor;blood test;

Countries

China

Contacts

Public ContactXiaoguang Shi

Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine

13301119560@163.com+86 13301119560

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026